Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for ImmunityBio (IBRX) over the last 5 years, with Sep 2025 value amounting to $946.6 million.

  • ImmunityBio's Shares Outstanding (Diluted Average) rose 35.62% to $946.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.6 million, marking a year-over-year increase of 35.62%. This contributed to the annual value of $700.4 million for FY2024, which is 37.71% up from last year.
  • Per ImmunityBio's latest filing, its Shares Outstanding (Diluted Average) stood at $946.6 million for Q3 2025, which was up 6.57% from $888.2 million recorded in Q2 2025.
  • ImmunityBio's Shares Outstanding (Diluted Average)'s 5-year high stood at $946.6 million during Q3 2025, with a 5-year trough of $382.7 million in Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $686.9 million (2024), whereas its average is $665.4 million.
  • Data for ImmunityBio's Shares Outstanding (Diluted Average) shows a peak YoY spiked of 57.06% (in 2024) over the last 5 years.
  • Over the past 5 years, ImmunityBio's Shares Outstanding (Diluted Average) (Quarterly) stood at $389.2 million in 2021, then climbed by 2.74% to $399.9 million in 2022, then climbed by 27.19% to $508.6 million in 2023, then spiked by 37.71% to $700.4 million in 2024, then surged by 35.62% to $946.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $946.6 million for Q3 2025, versus $888.2 million for Q2 2025 and $853.2 million for Q1 2025.